Clinical Trial Update: Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study [EARLY_Phase 1]

View source ↗

Summary

This document describes a single-center Phase 1 exploratory study evaluating autologous CAR-T cell therapy for refractory or relapsing ulcerative colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Autologous CAR-T Cell Therapy

Snippet

Sponsor: Hebei Senlang Biotechnology Inc., Ltd. | Conditions: UC | EARLY_Phase 1 | Status: RECRUITING